Gregory P. Bisson, MD, MSCE
|Office Location||832, Blockley Hall|
|CCEB Appointment||Senior Scholar, Epidemiology|
|Primary Faculty Appointment||Assistant Professor of Medicine, Infectious Diseases Division, University of Pennsylvania Perelman SOM|
|DBE Appointment||Assistant Professor of Epidemiology|
Dr. Bisson is an Assistant Professor in the Department of Medicine's Infectious Disease Division and a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania. He is committed to pursuing clinically important research questions in the area of Human Immunodeficiency Virus (HIV) infection, focusing primarily on the application of epidemiologic methods to the study of the natural history and treatment of clinically important viral and fungal co-infections. In addition, Dr. Bisson is committed to conducting operations research designed to facilitate public health approaches to the rapid delivery, or scale-up, of highly active antiretroviral therapy (HAART) in the developing world. A goal of his research is to use to improve the treatment of HIV-infected individuals in resource constrained settings. Dr. Bisson has received multiple grants for his research, including a K23 Mentored Career Development Award, a National Research Science Award (F32), a K12 Career Development Award in Translational Research, a Center for AIDS Research (CFAR) Developmental Core Piolet award, a Doris Duke Charitable Foundation award on Operations research on AIDS Care in Afirca (ORACTA), a Doris Duke Clinical Scientist Development Award (2008), and a Research Project Grant (RO1) evaluating outcomes in HIV/TB from the National Institutes of Allergy and Infectious Diseases. Dr. Bisson was the first research scientist at the University of Pennsylvania to begin formal research studies in Botswana and has been a leader in creating Penn’s main international research program – the Botswana UPenn Partnership. Projects of substantial impact led by Dr. Bisson include one of the first studies from Africa documenting the deleterious effects of greater out-of-pocket costs of HAART regimens on patient outcomes and a study demonstrating that monitoring adherence to HAART was more accurate than monitoring WHO-advocated CD4 count changes in individuals in resource-limited settings. This latter study was described in an accompanying editorial in PLoS Medicine as a "Paradigm shift" in preventing HIV drug resistance. The PLoS Medicine paper can be found here: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050109
Medicine 304, Instructor (2004). Hospital of the University of Pennsylvania, Philadelphia, PA.
Epidemiology 656, Instructor (2005). Epidemiological Research Methods in Infectious Diseases. Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA.
Clinical Evaluative Sciences â€“ Introduction to Epidemiology, Instructor (2005). Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA.
African Studies Graduate Seminar (AFST 701) Lecturer (2006). University of Pennsylvania, Philadelphia, PA.
Fundamentals of Epidemiology (HSOC 230) Lecturer (2006). Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA.
Issues in Protocol Research Protocol Development (EP560). Group Leader. Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA.
Bisson GP, Frank I, Gross R, Lo Re V, Strom J, Wang X, Gaolathe T, Ndwapi N, Friedman H, Strom B, Dickenson D.: Out-of-pockect Cost of Highly Active Antireoviral Therapy Limits HIV Treatment Response in Botswana's Private Sector. AIDS 20(9): 1333-1336, June 2006.
Bisson GP, Gross R, Strom J, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom B, Faolathe T, Ndwapi N.: Diagnostic accuracy of CD4 cell count increase for virologic reaponse after initiating highly active antiretrovial therapy. AIDS 21(12): 1613-1619, August 2006.
Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, Mogorosi M, Avalos A, Friedman H, Dickinson D, Frank I, Ndwapi N.: Overestimates of Survival after HAART: Implications for Monitoring Global Scale-up Efforts. PLoS ONE 3(3), March 2008.
Bisson GP, Gross R, Bellamy S, Rollins C, Chittams J, Frank I, Maartens G, Nachega J.: Pharmacy Refill Assessment Compared With CD4 Count Monitoring for Predicting Virologic Failure Among HIV-Infected Patients on Highly Active Antiretroviral Therapy. PLoS Medicine 5(5), May 2008.
Bisson GP, Nthobatsong R, Thakur R, Lesetedi G, Vinekar K, Tebas P, Gluckman S, Gaolathe T, MacGregor R.: The use of HAART is associated with decreased risk of death during initial treatment of Cryptococcal meningitis in HIV-infected adults in Botswana. JAIDS 49(2): 227-229, October 2008.
Gross R, Aplenc R, TenHave T, Foulkes A, Thakur R, Mosepele M, Barrett J, Flexner C, Strom B, Bisson GP: Slow Efavirenz Metabolism Genotype is Common in Botswana. JAIDS 49(3): 336-337, November 2008.
Kessler J, Ponce P, Saleshando G, Gluckman S, Friedman H, Bisson GP: Risk Factors for Failure to Be Offered Routine HIV Testing Among Adult Medical Inpatients in Botswana. JAIDS 47(4): 525-526, 2008.
Vinnard C, Winston C, Wileyto P, MacGregor RR, and Bisson GP: Isoniazid Resistance and Death in Patients with Tuberculous Meningitis: A Retrospective Cohort Study. British Medical Journal 6: 341:c4451, Sep 2010.
Steele K, Thakur R, Nthobatsang R, Steenhoff A, Bisson GP: In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Medical Mycology Page: 1-4, 2010.
Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP: Multidrug Resistant Tuberculous Meningitis in the United States, 1993-2005. Journal of Infection 2011 doi:10.1016/j.jinf.2011.07.005.
Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP.: Isoniazid-resistant tuberculous meningitis, United States, 1993-2005. Emerg Infect Dis.(3), 539-42, March 2011.
Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC.: Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother.(4), 1527-32, 2011.
Gupta A, Nadkami G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N.: Early mortality in adults initiating antiretroviral therapy (ART) in low and middle-income countries (LMIC): A systematic review and meta-analysis. PLoS ONE 6(12), December 2011.
Steele K, Steenhoff A, Newcomb C, Rantleru T, Nthobatsang R, Lesetedi G, Bellamy S, Nachega J, Gross R, Bisson GP.: Early Mortality and AIDS Progression Despite High Initial Antiretroviral Therapy Adherence and Virologic Suppression in Botswana. PLoS ONE 6(6), 2011.
Vinnard C, Winston C, Wileyto P, Macgregor RR, Bisson GP.: Factors Associated with Isoniazid Resistant Tuberculous Meningitis in the United States, 1993 to 2005, Mar; [Epub ahead of print] Emerging Infectious Diseases, 2011.
Bisson G, Mehaffy C, Broeckling C, Prenni J, Rifat D, Lun D, Burgos M, Weissman D, Karakousis P, Dobo K, : "Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampicin-resistant, rpoB-mutant Mycobacterium tuberculosis" Journal of Bacteriology In press.
Han J, Crane H, Bellamy S, FRANK I, Cardillo S, Bisson GP, : HIV Infection and Glycemic Response to Newly Initiated Diabetic Medical Therapy. AIDS In press.
Zetola N, Modongo C, Kip E, Gross R, Bisson GP, Collman R, : Alcohol use and abuse among patients with multi-drug resistant tuberculosis in Botswana. International Journal of Tuberculosis and Lung Disease In press.